OCUP
Price:
$1.17
Market Cap:
$31.74M
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and dia...[Read more]
Industry
Biotechnology
IPO Date
2005-11-10
Stock Exchange
NASDAQ
Ticker
OCUP
According to Ocuphire Pharma, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.17. This represents a change of 139.50% compared to the average of -0.91 of the last 4 quarters.
The mean historical PE Ratio of Ocuphire Pharma, Inc. over the last ten years is -321.21. The current -2.17 PE Ratio has changed -32.44% with respect to the historical average. Over the past ten years (40 quarters), OCUP's PE Ratio was at its highest in in the June 2017 quarter at 942.27. The PE Ratio was at its lowest in in the September 2014 quarter at -9091.27.
Average
-321.21
Median
-2.16
Minimum
-3194.75
Maximum
3.93
Discovering the peaks and valleys of Ocuphire Pharma, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 32.83%
Maximum Annual PE Ratio = 3.93
Minimum Annual Increase = -501.36%
Minimum Annual PE Ratio = -3194.75
Year | PE Ratio | Change |
---|---|---|
2023 | -6.51 | -265.46% |
2022 | 3.93 | -501.36% |
2021 | -0.98 | 1.97% |
2020 | -0.96 | 32.83% |
2019 | -0.72 | -66.04% |
2018 | -2.13 | -2.60% |
2017 | -2.19 | -33.12% |
2016 | -3.27 | -28.34% |
2015 | -4.56 | -99.86% |
2014 | -3194.75 | -3.64% |
The current PE Ratio of Ocuphire Pharma, Inc. (OCUP) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.18
5-year avg
-1.05
10-year avg
-321.21
Ocuphire Pharma, Inc.’s PE Ratio is less than Reviva Pharmaceuticals Holdings, Inc. (-0.96), greater than Protalix BioTherapeutics, Inc. (-5.79), greater than EyePoint Pharmaceuticals, Inc. (-6.11), less than SELLAS Life Sciences Group, Inc. (-2.06), less than Reviva Pharmaceuticals Holdings, Inc. (-0.96), less than Eyenovia, Inc. (-0.70), less than Cognition Therapeutics, Inc. (-0.65), less than TransCode Therapeutics, Inc. (-0.18), less than Kodiak Sciences Inc. (-1.31), less than Checkpoint Therapeutics, Inc. (0), greater than Mustang Bio, Inc. (-2.90), less than Fortress Biotech, Inc. (-0.18), less than Rigel Pharmaceuticals, Inc. (-0.69), less than Fortress Biotech, Inc. (100.09), less than CTI BioPharma Corp. (-0.69), greater than null (-30.90),
Company | PE Ratio | Market cap |
---|---|---|
-0.96 | $30.78M | |
-5.79 | $85.31M | |
-6.11 | $792.64M | |
-2.06 | $79.13M | |
-0.96 | $27.03M | |
-0.70 | $41.84M | |
-0.65 | $20.27M | |
-0.18 | $7.85M | |
-1.31 | $258.86M | |
0 | $149.35M | |
-2.90 | $9.28M | |
-0.18 | $48.05M | |
-0.69 | $388.32M | |
100.09 | $47.13M | |
-0.69 | $1.20B | |
-30.90 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ocuphire Pharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Ocuphire Pharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Ocuphire Pharma, Inc.'s PE Ratio?
How is the PE Ratio calculated for Ocuphire Pharma, Inc. (OCUP)?
What is the highest PE Ratio for Ocuphire Pharma, Inc. (OCUP)?
What is the 3-year average PE Ratio for Ocuphire Pharma, Inc. (OCUP)?
What is the 5-year average PE Ratio for Ocuphire Pharma, Inc. (OCUP)?
How does the current PE Ratio for Ocuphire Pharma, Inc. (OCUP) compare to its historical average?